Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Angelopoulou
Observed names:
M Angelopoulou,
M K Angelopoulou,
M. K. Angelopoulou,
M.K Angelopoulou,
M.K. Angelopoulou,
MK Angelopoulou,
Maria K. Angelopoulou
show all 7
Institutions:
National and Kapodistrian University of Athens,
Laiko General Hospital of Athens
Observed institutions:
City Of Hope National Medical Center,
National and Kapodistrian University of Athens,
City of Hope,
Laiko General Hospital of Athens
ORCID:
0000-0002-1596-3630
Observed ORCID:
0000-0002-1596-3630
OpenAlex ID:
A5079303968
B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders.
1999
·
G A Pangalis
, M K Angelopoulou
, et al.
·
PubMed
·
115
Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
2007
·
C Kalpadakis
, GA Pangalis
, et al.
·
Hematological Oncology
·
109
Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients
2001
·
M.-C. Kyrtsonis
, T. Vassilakopoulos
, et al.
·
Annals of Hematology
·
91
Adhesion molecules in B-chronic lymphoproliferative disorders.
1999
·
M K Angelopoulou
, F N Kontopidou
, et al.
·
PubMed
·
65
Sjögren's syndrome associated with multiple myeloma
2000
·
E. Terpos
, M. K. Angelopoulou
, et al.
·
Annals of Hematology
·
30
Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies
2004
·
R Rodriguez
, P Parker
, et al.
·
Bone Marrow Transplantation
·
26
Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib
2011
·
G Georgiou
, A Efthymiou
, et al.
·
Leukemia
·
17
Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period
2000
·
GA Pangalis
, MN Dimopoulou
, et al.
·
Medical Oncology
·
15
Genetic polymorphisms and risk of MALT lymphoma in Greek population
2021
·
A. Velissari
, T.P Vassilakopoulos
, et al.
·
Current Research in Translational Medicine
·
7
Pf297 Comparison of Rituximab Dose‐adjusted Epoch (r‐da‐epoch) With Rituximab‐chop (r‐chop) Chemotherapy in Primary Mediastinal Large B‐cell Lymphoma (pmlbcl)
2019
·
T. Vassilakopoulos
, Z. Mellios
, et al.
·
HemaSphere
·
5
Rituximab‐dose‐adjusted Epoch (r‐da‐epoch) in Primary Mediastinal Large B‐cell Lymphoma (pmlbcl): Real‐life Experience on 190 Patients From 3 Mediterranean Countries
2021
·
T. Vassilakopoulos
, B. Ferhanoglu
, et al.
·
Hematological Oncology
·
4
PDF
Expression of three different ATP ‐binding cassette transporters and correlation to chemoresistance in acute myeloid leukemia
2014
·
D. Palaiologou
, P. Panayiotidis
, et al.
·
International Journal of Laboratory Hematology
·
4
REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS
2023
·
T. Vassilakopoulos
, B. Ferhanoglu
, et al.
·
Hematological Oncology
·
2
PDF
PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB‐CHOP (RCHOP) ± RADIOTHERAPY (RT)
2019
·
T.P. Vassilakopoulos
, S.G. Papageorgiou
, et al.
·
Hematological Oncology
·
2
Treatment Strategies and Prognostic Factors for the Outcome of Patients With Hodgkin Lymphoma Experiencing Very Late Relapses After Chemotherapy ± Radiotherapy
2023
·
T. P. Vassilakopoulos
, A. Liaskas
, et al.
·
Hematological Oncology
·
1
PDF
P1229: Rituximab-dose-adjusted Epoch (r-da-epoch) in Primary Mediastinal Large B-cell Lymphoma (pmlbcl): Real-life Experience on 225 Patients From 4 Countries
2022
·
T. Vassilakopoulos
, B. Ferhanoglu
, et al.
·
HemaSphere
·
1
Pb1936: Paroxysmal Nocturnal Hemoglobinuria and Thrombosis: a Multicentric Retrospective Study
2022
·
S. Chatzileontiadou
, N.-E. Loutsidi
, et al.
·
HemaSphere
·
1
P1230: Pet/ct Imaging for Response Assessment and Treatment Guidance After Rituximab-dose-adjusted-epoch(r-da-epoch) in Primary Mediastinal Large B-cell Lymphoma (pmlbcl):the Greek Experience on 107 Patients
2022
·
T. Vassilakopoulos
, A. Piperidou
, et al.
·
HemaSphere
·
1
Ps1089 Pet-scan for Response Assessement After Rituximab-dose-adjusted-epoch (r-da-epoch) in Primary Mediastinal Large B-cell Lymphoma (pmlbcl): Clinical and Prognostic Significance
2019
·
T. Vassilakopoulos
, C. Chatzidimitriou
, et al.
·
HemaSphere
·
1
Pf472 Very Late Realapses (vlr) ≥5 Years After Initial Treatment With Chemotherapy±radiotherapy (ct±rt) in Hodgkin Lymphoma (hl): a Join Study on Treatment Strategies and Prognostic Factors for the Outcome
2019
·
T. Vassilakopoulos
, A. Liaskas
, et al.
·
HemaSphere
·
1
PDF
Response to ‘PET after response to R-CHOP in primary mediastinal large B-cell lymphoma’
2016
·
TP Vassilakopoulos
, S Papageorgiou
, et al.
·
Leukemia
·
1
Prognostic Contribution of the New Immunoglobulin (Ig) Biomarkers (Freelite™ and Hevylite™) in Waldenstrom’s Macroglobulinemia (WM)
2012
·
M-C. Kyrtsonis
, E. Koulieris
, et al.
·
American Journal of Medicine and Medical Sciences
·
1
Baseline Serum C-Reactive Protein Levels (Crp) in Hodgkin Lymphoma (Hl): Correlations With Clinical and Laboratory Parameters and Prognostic Significance Under Anthracycline-Based Chemotherapy
2011
·
Theodoros P. Vassilakopoulos
, Vasiliki Pappi
, et al.
·
1
The Evolving Role of Obinutuzumab in the Treatment of Splenic Marginal Zone Lymphoma
2026
·
Maria K. Angelopoulou
, Eliana Α. Konstantinou
, et al.
·
Case Reports in Hematology
344 | SERUM β2‐ MICROGLOBULIN LEVELS IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: AN UNRECOGNIZED PROGNOSTIC FACTOR
2025
·
T. Vassilakopoulos
, M. Arapaki
, et al.
·
Hematological Oncology
PDF
Show more works
View as search
Works count:
28
Citation count:
500
H-index:
8
I10-index:
8
Year
Topic
Type